LM-299
Based on 1 Customer Validation
LM-299 is a bispecific antibody targeting PD-1 and VEGF with anti-tumor activity. The dual binding activity of LM-299 is achieved through the effective binding of its Fab-terminal anti-VEGF-A antibody to human VEGF-A, as well as the blocking effect of its Fc-terminal anti-PD-1 antibody on the PD-1/PD-L1 pathway. LM-299 binds to and modulates PD-1 and VEGF. LM-299 can be used in studies related to advanced malignant tumors, advanced solid tumors, and advanced non-small cell lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.78%
- Molecular Weight:175.49 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Target
PD-1 & VEGF
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human PD-1 Protein, His Tag can bind LM-299. The EC50 for this effect is 164.3 ng/mL. -
Immobilized Human VEGF165 Protein,hFc Tag can bind LM-299. The EC50 for this effect is 77.9 ng/mL.
Product Details
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Reinheit
95.78%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)